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Abstract
Transduction of exogenous T cell receptor (TCR) genes into patients’ activated peripheral blood T
cells is a potent strategy to generate large numbers of specific T cells for adoptive therapy of
cancer and viral diseases. However, the remarkable clinical promise of this powerful approach is
still being overshadowed by a serious potential consequence: mispairing of the exogenous TCR
chains with endogenous TCR chains. These “mixed” heterodimers can generate new specificities
that result in graft-versus-host reactions. Engineering TCR constant regions of the exogenous
chains with a cysteine promotes proper pairing and reduces the mispairing, but, as we show here,
does not eliminate the formation of mixed heterodimers. By contrast, deletion of the constant
regions, through use of a stabilized Vα/Vβ single-chain TCR (scTv), avoided mispairing
completely. By linking a high-affinity scTv to intracellular signaling domains, such as Lck and
CD28, the scTv was capable of activating functional T cell responses in the absence of either the
CD3 subunits or the co-receptors, and circumvented mispairing with endogenous TCRs. Such
transduced T cells can respond to the targeted antigen independent of CD3 subunits via the
introduced scTv, without the transduced T cells acquiring any new undefined and potentially
dangerous specificities.
Keywords
T cell receptors; peptide/MHC; retroviral transduction; adoptive T cell therapy
1This work was supported by grants from the NIH, GM55767 (to DMK), CA097296 (to HS and DMK), CA033084 and CA18029 (to
PDG), a grant from the James S. McDonnell Foundation (to DMK), and grant 7040 from the Leukemia and Lymphoma Society (to
PDG). BE was supported by a Research Fellowship of the DFG; JDS was supported by the Samuel and Ruth Engelberg/Irvington
Institute Fellowship of the Cancer Research Institute.
2Address correspondence to: David M. Kranz, Department of Biochemistry, University of Illinois, 600 S. Mathews Ave., Urbana, IL
61801, Phone: 217-244-2821, FAX: 217-244-5858, d-kranz@illinois.edu.
Conflict of interest
The authors do not have a conflict of interest.
NIH Public Access
Author Manuscript
Gene Ther. Author manuscript; available in PMC 2013 April 1.
Published in final edited form as:














The potential of T cells in eliminating cancer cells has been demonstrated in numerous
studies. However, when cancer becomes clinically apparent, the patient’s T cells have
clearly failed to effectively reject the malignancy. Active immunization is being attempted
to make the patient’s own T cells recognize and destroy the cancer, but this approach is
complicated by the fact that T cells specific for the cancer cells, particularly those with high
avidity or affinity, may be suppressed or been deleted by central or peripheral tolerance. To
improve the T cell response to cancer, recent approaches have combined adoptive T cell
transfer with TCR gene therapy, in which a TCR of desired specificity and affinity is
transduced into patients’ ex vivo activated T cells 1. This approach shows evidence of
therapeutic promise 2,3 but also carries potential dangers 4.
T cells recognize foreign antigens, in the form of peptides bound to products of the major
histocompatibility complex (pepMHC), through a heterodimeric T cell receptor (TCR)
consisting of α and β chains 5. A recognized complication of TCR gene therapy is the ability
of introduced TCR α and β chains to mismatch with endogenous T cell receptors 6–9. In two
recent studies, TCR mispairing between introduced and endogenous TCR α and β chains led
to undesirable reactivities. In the first study using a mouse model system, overt
autoimmunity (graft-versus-host disease) was observed, to varying degrees, in five different
TCR systems 4. The other study with human T cells showed that mismatched heterodimers
caused off-target toxicity, with an estimate of one of every ten mixed TCR heterodimers
causing neoreactivity 10. These findings reinforce the idea that TCR mispairing could have
detrimental, potentially dangerous, consequences.
A number of approaches have been developed to minimize the extent of mispairing
(reviewed in 8,9,11-14). These have included the use of hybrid human TCR chains containing
mouse constant domains, which associate preferentially with each other rather than with the
endogenous TCR chains containing human constant domains 15. Another strategy involved
fusion of the TCR chains to CD3ζ transmembrane and signaling subunits, also leading to
preferential pairing of the exogenous TCR chains 16. Finally, several laboratories have
shown that the substitution of non-native cysteine residues within the constant domains of
the introduced TCR 17 also promotes pairing of the exogenous chains, presumably through
the formation of an additional disulfide bond at the Cα:Cβ interface 18–20, significantly
reducing the extent of mispairing and graft-versus-host disease in mouse models of TCR
gene therapy 4. However, the full extent to which these strategies can prevent TCR chain
mispairing is unclear.
An additional challenge of the TCR gene therapy approach is that the levels of exogenous
αβ TCRs expressed on the surface of T cells is reduced by the concurrent expression of
endogenous αβ TCRs, since the total surface levels of TCR are controlled by the availability
of the CD3 subunits, especially the ζ subunits 21,22. As CD3 subunits are limiting, even the
optimized pairing strategies described above are likely to result in lower surface levels for
some exogenous TCRs, compared to a single, homogenous αβ TCR. Because TCR surface
levels directly impact antigen sensitivity 23, it would be useful to develop strategies that
enhance the levels of the exogenous TCRs. To this end, a number of TCR modifications,
such as codon and vector optimization have been shown to improve surface levels of
exogenous TCRs 24–26.
Various single-chain TCR chimeras have been used in attempts to limit the problems
associated with pairing of endogenous TCRs. These included three-domain TCRs that
contain other signaling domains such as the CD3ζ intracellular domain
(VαVβCβCD3ζ) 7,27,28 and three domain constructs along with a separate Cα domain 29.
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While these constructs mediate antigen-specific T cell activity, the extent of TCR mispairing
and the quantitative comparisons of peptide activity with conventional two-chain αβ T cells
has often not been examined. Single-chain T cell receptors consisting of only the TCR
variable domains (VαVβ in principle would completely eliminate mispairing, but have been
problematic due to instability of Vα and Vβ domains in the absence of constant domains 30.
Here we show that three domain TCR constructs (VαVβCβ) yield mispaired receptors in the
presence of an endogenous α chain because of the contained Cβ domain. Stabilized two
domain TCRs (VαVβ) with chimeric signaling domains avoid mispairing altogether and
mediate T cell activity. The high-affinity scTv linked to intracellular signaling domains, Lck
and CD28, was capable of activating T cells in the absence of either the CD3 subunits or the
co-receptors CD4 or CD8. The scTv system also worked with a human construct specific for
an HLA.A2 – restricted peptide derived from the HIV-Gag protein. Our novel approach
preserves the endogenous TCRs to potentially be triggered via intentional immunization or
homeostatic proliferative signals, while permitting the introduced scTv TCRs to respond to
the targeted antigen independent of CD3 subunits, without the transduced T cells acquiring
any new undefined and potentially dangerous specificities.
Results
Three-domain single-chain TCR (VαVβCβ) containing a non-native Cβ cysteine mispairs
with endogenous TCR chains
Various studies have suggested that a single-chain TCR construct consisting of tandem
VαVβCβ domains could minimize the potential for mispairing with endogenous TCRs.
Inclusion of a non-native cysteine in C regions represents another strategy to minimize such
mispairing. Since the Cα:Cβ interaction contributes significant binding energy to these
pairing interactions, we decided to explore whether a single-chain TCR (VαVβCβ) that
contains a non-native Cβ cysteine would mispair with an endogenous α chain (VαCα),
presumably through the interaction of the Cβ with the Cα. To directly assess this, we took
advantage of high-affinity probes for two different, properly associated VαVβ pairs. The
first probe, for the 2C TCR, is a clonotypic antibody, denoted 1B2, that binds only to
properly associated 2C VαVβ with an affinity of 1 nM 31. The second probe, for the mutated
2C TCR denoted m33 TCR, is the SIY/Kb ligand that binds only to properly associated m33
VαVβ with an affinity of 30 nM 32. The mutations that convert 2C to the high-affinity m33
reside in the Vα CDR3 region, and prevent binding of 1B2 33. In addition, since the affinity
of the SIY/Kb complex for 2C is low (30 µM), this tetramer bound by m33 only binds to the
2C TCR in the presence of CD8 34.
Expression of the m33 three-domain (VαVβCβ) construct (Figure 1) in the T cell hybridoma
58−/− resulted in cells that were cell surface positive for Cβ and weakly positive for staining
with SIY/Kb (Figure 2A), but as expected were negative for staining with 1B2. The vector
containing the m33 three-domain construct was then transduced into 58−/− cells together
with the α chain from 2C (VαCα). These cells were not only positive for anti-Cβ and SIY/
Kb, but were strongly positive for 1B2. The only way for the 2C α chain to reconstitute the
1B2-binding site is for the VβCβ region of the m33 three-domain construct to associate with
the 2C α chain on the surface. As a consequence, it is likely that a fraction of cell surface
receptors consist of the 2C α chain paired with the m33 β chain, while another fraction of
cell surface receptors consists of the m33 Vα and Vβ domains of the three-domain construct
properly associated. Thus, the three-domain construct can mispair with endogenous TCRs,
and the nonnative Cβ cysteine did not prevent pairing with the endogenous α chain that
lacks a non-native Cα cysteine. This result is consistent with a previous result that adding
the C region cysteine mutation to a single introduced exogenous chain reduced but did not
prevent mispairing with an endogenous chain 18.
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To verify that the three-domain construct was capable of mispairing with another TCR,
when both the α and β chains were expressed, we used a mouse TCR called 3D that is
specific for WT-1/Db. This TCR included mutations that improve the binding to WT-1/Db,
as engineered by T cell display (unpublished results). The 3D TCR allowed detection of
binding to a WT-1/Db dimer in the absence of co-receptor CD8, and thus, like m33 the
pepMHC can be used directly to probe for properly associated 3D αβ. The 3D TCR was
transduced with unmodified constant domains (Cα48:Thr, Cβ57:Ser) in order to provide a
direct test of pairing of the three-domain m33 construct with the endogenous TCR chains.
The m33 three-domain construct was then introduced into the 3D TCR expressing 58−/− T
cells and cells were sorted with an antibody to Vβ8 (m33). Surface levels of (i) m33 three-
domain construct alone, (ii) 3D TCR construct alone, or (iii) the combination of 3D TCR
and m33 three-domain constructs were examined with anti-mouse Vβ8 (m33) (Figure 3A),
anti-mouse Vβ10 (3D TCR) (Figure 3B), and WT-1/Db Ig dimmer (3D TCR) (Figure 3C).
In cells co-expressing the m33 and 3D constructs, binding to the 3D ligand WT1/Db (Figure
3C) was significantly reduced, and binding to the m33 Vβ was significantly increased
(Figure 3A). These results would appear to reflect mispairing of the m33 three-domain
construct with the 3D α chain, resulting in a decrease in 3D heterodimers and the associated
reduction of binding WT1/Db, and an increase in m33 Vβ expression from mispairing with
the 3D α chain. The coexpressed 3D TCR and m33 three-domain construct showed similar
levels of Vβ10 (Figure 3B) as the 3D TCR alone potentially because of ββ homodimers, as
observed by others expressing murine constant domains 20.
Expression of a scTv (VαVβ) avoids mispairing
As the three-domain construct mispaired with endogenous TCR chains, we reasoned it might
be possible to use a single-chain TCR that lacked a Cβ region in order to completely avoid
mispairing. Similar approaches have used scFv fragments as chimeric antigen receptors
(CAR), consisting of various fused signaling domains 35. Although analogous single-chain
TCR molecules are typically unstable without the Cβ domain, we have shown that it is
possible to engineer scTv (VαVβ) by incorporating stabilizing mutations in the V
regions 30,36,37.
To test this strategy, we cloned the stabilized scTv of m33 as a fusion with CD28, CD3ζ,
and Lck domains. The inclusion of Lck has been shown to improve T cell cytokine release
in response to antigen with other chimeric antigen receptor constructs, where the
extracellular binding domains were derived from MHC molecules 38. The m33 scTv fusion
was introduced into 58−/− alone or with the 3D TCR and expressed at high levels on the
surface of the 58−/− line, as detected with both the anti-Vβ8 antibody and the SIY/Kb
(Figure 4). The binding of SIY/Kb indicated that the Vα and Vβ domains were associated
appropriately at the cell surface. Furthermore, the expression of the m33 scTv was not
influenced by expression of the 3D TCR, nor was the 3D TCR surface levels affected by the
m33 scTv. These results suggest that significant mispairing was not occurring.
Surface levels of the stabilized scTv are higher than conventional TCR
To determine whether the surface levels of the scTv fusions of the TCR were comparable to
the conventional αβ TCR/CD3 complex, we examined transduced cells expressing the m33
scTv fusion or the full length m33 αβ chains in the absence of endogenous TCRs or the CD8
co-receptor. The scTv fusion was expressed at approximately five-times the surface level
(based on mean fluorescence intensities) of the full-length αβ TCR, as detected with anti-
Vβ8 antibody (Figure 5A). The wild type, low affinity 2C TCR expressed as either a scTv
fusion or in the full-length form was detected at nearly identical levels to m33 (Figure 5A).
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Since typical binding studies with pepMHC tetramers take advantage of the avidity achieved
through the presence of many TCRs per cell, we next examined the binding of SIY/Kb
tetramers to low (2C) and high-affinity (m33) forms of the TCR expressed as either a scTv
fusion or full αβ TCR. As previously described 34,39,40, the αβ full-length, high-affinity TCR
m33, but not the 2C, was capable of binding tetramers in the absence of CD8. The higher
surface levels of the scTv forms yielded enhanced staining with the SIY/Kb tetramer,
including significant binding by the 2C scTv despite its relatively low affinity (KD = 30 µM).
Full titrations with SIY/Kb tetramer revealed that the 2C low affinity scTv bound even
higher levels than the high-affinity m33 expressed as a conventional αβ TCR, despite the
1000-fold higher affinity of m33 (Figure 5C). This finding highlights the importance of
surface densities have on the binding of multimeric ligands.
Efficient T cell activation is mediated by the stabilized scTv fusions
To examine the activation of T cells mediated by the scTv fusions, we examined IL-2
release by the transduced 58−/− lines using various stimulating ligands. As the 58−/− cell
line was derived from an AKR mouse thymoma 41 and does not express Kb, it is unable to
cross-present the SIY peptide. The full-length TCR was assembled with CD3 subunits,
whereas surface expression of the scTv did not require CD3 as evidenced by the absence of
staining with the anti-CD3ε antibody (Figure 6A). Despite the absence of CD3ε from the
surface of cells transduced with scTv fusions, these cells were efficiently stimulated by anti-
Vβ antibody immobilized on plates (Figure 6B). Cells that expressed the conventional αβ
TCR were also stimulated by immobilized anti-CD3ε, whereas the scTv cells were not
simulated by anti-CD3 antibodies (Figure 6B).
Antigen-presenting cells (T2-Kb) were used in the presence of various concentrations of the
SIY peptide to determine if cells transduced with different forms of the TCRs mediated
peptide dependent, CD8-independent activity. As described previously 32,40,42, CD8-
negative cells transduced to express the m33 full-length TCR, but not the 2C TCR,
responded to SIY peptide in the presence of T2-Kb (Figure 6C). The m33 scTv fusion
stimulated activity at approximately the same concentration of peptide as the full-length
m33 αβ TCR. In contrast, the 2C scTv was not stimulated by SIY-loaded T2-Kb cells,
despite the high surface levels of the scTv form and the ability of the scTv to bind to SIY/Kb
multimers (Figure 5C). Thus, in the absence of CD8, avidity did not overcome the
requirement for an inherent binding threshold 40. However, immobilized SIY/Kb tetramers
were capable of stimulating the 2C scTv fusions to a greater extent than the T2-Kb presented
antigen (Figure 6D), consistent with our previous observations that low affinity TCRs can be
stimulated under these conditions 40. Using a soluble high-affinity TCR as a probe, we have
shown that the density of immobilized SIY/Kb is within a few fold of SIY/Kb on T2-Kb
APCs. On the surface of T2-Kb cells, pulsed with 5 µM SIY, the estimated density was 2.5 ×
108 molecules/µm2; at 250 nM tetramer immobilized on plastic, which is a stimulatory
concentration for the 2C scTv T cells, the estimated density was 1.4 × 108 molecules/µm2
(40 and data not shown). Thus, the stimulation by pepMHC immobilized on plastic does not
appear to be due to higher antigen density (although we can not rule out that it is due to
higher localized densities of the ligand). A previous study has shown similar observations
that immobilization can enhance T cell activity, but the mechanism is unknown 43. In our
previous study, we showed that immobilized SIY/Kb elicited higher levels of pERK in the
2C full-length TCR 58−/− cells, but we have been unable to monitor Ca2+ levels in these T
cell hybridoma lines 40.
To examine if CD8 can improve the response of the 2C scTv fusion to antigen, we
introduced the 2C scTv into CD8αβ+ 58−/− cells (Figure 6E). T cell hybridomas with CD8
and the 2C scTv showed increased antigen sensitivity in response to T2-Kb cells (Figure 6F),
presumably even without the assembled CD3 complex. This result suggests that the CD8
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coreceptor might provide enhanced signaling through the scTv receptor, perhaps by
recruiting the kinase Lck to the intracellular domains of the receptor through extracellular
interactions between CD8 and cognate class I MHC molecules, and thereby also enhancing
the avidity of the T cells for the target.
Finally, to evaluate the ability of the high-affinity m33 scTv constructs to redirect primary T
cell activity, an m33 scTv receptor that contained intracellular signaling domains comprised
of CD28, 4-1BB, and CD3ζ Figure 1, Vα−L-Vβ CD28,4-1BB,CD3ζ , was introduced into
primary T cells and T cell cytotoxicity was assessed in a 51Cr release assay. Antigen-
specific lysis of T2-Kb cells loaded with SIY at 1 µM was observed in both CD8+ (Figure
7A) and CD4+ (Figure 7B) polyclonal T cells, where activity was mediated by either the
conventional full-length TCR or the scTv receptor.
T cell activity mediated through a stabilized human scTv fusion
To examine the applicability of the scTv system to another TCR, a human TCR denoted
868, specific for HIV-Gag/HLA.A2 44, was introduced as an scTv construct. A stabilized
scTv mutant of the parental αβ 868 TCR, engineered by yeast display, exhibited high-
affinity for HIV-Gag (SL9)/HLA.A2 (KD < 2 nM) 45. The human 868 scTv was fused to the
same mouse intracellular signaling domains (Figure 8A) as with the 2C and m33 systems,
the construct was transduced into the 58−/− T cell hybridoma, and the 868 scTv was detected
on the surface as monitored by anti-human Vβ5.2 antibody (Figure 8B). The 868 scTv cell
line was activated by SL9 peptide presented by T2 cells and by plate-bound SL9/HLA.A2
tetramer, but not the null peptide ligands WT1 or Tax (Figure 8C,D), consistent with our
results with other TCR chains.
The 868 scTv, and a conventional full-length αβ TCR against the WT-1 peptide as control,
were introduced into activated polyclonal peripheral human T cells, and examined in a 51Cr
release assay (Figure 8E). Only T cells that expressed the 868 scTv were able to specifically
lyse target cells that bear the SL9/HLA.A2 complex. Collectively, these experiments show
that scTv chimeric receptors can be generated from various TCRs, that these receptors retain
antigen specificity, and that this strategy can be used to generate antigen-specific T cells
from a population of polyclonal human T cells that are capable of mediating effector
functions against relevant pepMHC targets.
Discussion
Recent studies have introduced virus- or cancer-specific TCRs into T cells as a strategy to
provide a patient with an enhanced T cell response, and ongoing studies are attempting to
optimize this approach 1,2,9,13,14. In a related strategy to provide tumor-reactive T cells,
transduced T cells expressing chimeric antigen receptors (CARs) that contain a scFv fused
to intracellular T cell signaling domains (e.g. CD28, CD3ζ, and Lck) have entered clinical
testing 35. Combining these approaches, several labs have attempted to use single-chain,
three-domain TCRs (VαVβCβ) that can mediate proximal signaling through fused
intracellular signaling domains 7,27,46. In principle, the advantages of these TCR fusions are
that a single gene product could recognize target cell pepMHC antigens and stimulate the
effector functions associated with T cells, independent of endogenous CD3 molecules 14.
However, the three-domain strategy has been limited in some instances because the TCR
surface levels are insufficient for recognition of low levels of antigen 28. Furthermore, while
the three-domain TCR construct provides the stability necessary for surface expression, we
show here that it does not avoid a major problem associated with use of exogenous TCRs in
gene therapy, mispairing with endogenous TCR chains. This mispairing has recently been
shown to result in neoreactivities 10, and T cell-induced graft-versus-host disease a mouse
model 4. Possibly relevant to the mispairing issue, the expression of two TCRs in the same T
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cell allowed tolerance of T cells expressing the self-reactive TCR to be overcome,
apparently by stimulation through the second TCR 47.
Improvements in surface levels of exogenous TCRs have been achieved by various methods,
including codon optimization to enhance transcription levels 48, regulation of αβ chain
stochiometry to improve proper pairing 49,50, inclusion of non-native cysteines 18,19,
modification of other residues in the C regions 26,51,52, substitution of mouse C regions in
human TCRs 15,53,54, or direct fusion of CD3ζ domains 16 to drive desired pairing of the
introduced chains. However, the diversity of αβ TCRs makes it unlikely that mispairing can
be completely avoided using these approaches. Therefore, attempts to avoid the problem
altogether have involved use of different recipient cell types such as γδ T cells 55–57, NK
cells 58, or oligoclonal populations of αβ T cells 4,59. However, these approaches also have
limitations, including difficulty isolating and transducing a sufficient numbers of cells for
adoptive transfer. A method to silence endogenous TCR has been developed using siRNA,
but the duration and efficiency of endogenous TCR suppression is unclear 60. It is worth
noting that because CD3ζ subunits are limiting in a T cell 22, several of these approaches
will lead to competition between some exogenous and endogenous TCRs for CD3, resulting
in lower levels of both receptors.
Our results show that the inclusion of a Cβ region with a non-native cysteine allowed
association with endogenous α chains, and that deletion of the Cβ effectively eliminated
pairing, within the limits of detection by flow cytometry (i.e. approximately 1,000
molecules/cell). The ability of α and β chains to pair is dependent on the interactions of the
Vα:Vβ regions and the Cα:Cβ regions, but the relative contributions of each are not known.
Assembly of the entire αβ/CD3 complex requires charged residues in the transmembrane
domains of the various subunits 61. While the association of the Cα and Cβ domains
presumably is the same among different TCRs, the Vα:Vβ interaction varies, and is
controlled by multiple residues at the interface including regions within the CDR3α and
CDR3β 30,62. Hence, TCR chain pairing studies often reveal “strong” or “weak” TCRs; and
the efficiency of a particular αβ association helps determine the surface levels of a TCR pair
in cells expressing multiple α and β chains 12,13,63. Our data demonstrates that a TCR with
Vα and Vβ regions alone is insufficient to drive detectable association with an endogenous α
and β TCR chains, suggesting that the dimerization constants of the V regions is low, and a
large fraction of the association energy is driven by interactions between Cα and Cβ
regions 29. As with the original principle of linking VL and VH to form scFv fragments 64, the
scTv provides a strategy for forcing the association between the linked domains. In practice,
this is not trivial, and single-chain VαVβ fragments (scTv) are considerably less stable than
scFv fragments 30. Our lab has previously overcome this obstacle by engineering scTv with
key stabilizing mutations in the V regions 30,36,37, and here we show that these scTv can be
generated as fusions with intracellular signaling domains that can mediate T cell activation
following antigen recognition. While chimeric antigen receptors directed by scFv fragments
have been useful in targeting non-MHC restricted cell surface antigens, the recognition of
MHC-associated antigens by scTv fragments makes it possible to target the vast array of
intracellular antigens invisible to scFv on viable cancer or virally infected cells. In addition,
scTv can recognize antigens released by cancer cells and cross-presented by tumor stroma,
which can be critical for eradicating antigen-loss variants in a tumor mass and thereby
prevent relapse after therapy 65,66. In principle, scFv fragments specific for MHC-restricted
antigens could also be used for these purposes 67–70.
In order for a TCR, and presumably a scTv, to mediate activity in the absence of CD8 or
CD4 binding to the presenting MHC molecules, its affinity needs to be above a threshold of
about 1 µM 40. Because of this threshold limitation, the wild type TCR 2C (KD = 30 µM) did
not mediate activity against cell-presented antigen either as a scTv, or as a full-length TCR
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in the absence of CD8 (Figure 6C). Addition of the CD8 coreceptor provided some
improvement in antigen sensitivity. Optimization of the fused signaling domains may be
able to enhance the sensitivity of scTv, or possibly even overcome issues associated with
tolerance when T cells must function in a suppressive tumor environment (e.g. 71,72).
Nevertheless, it still remains questionable whether, in the absence of CD8, scTv that have
not been modified to increase affinity will be capable of targeting the pepMHC levels found
in many cancer or virus-infected cells. Fortunately, TCRs with affinities similar to those of
antibodies can be engineered 73. We show here that scTv forms of engineered TCRs
targeting a mouse pepMHC (SIY/Kb, m33 TCR) or the HIV Gag antigen (SL9/HLA.A2,
868 TCR) 44 can mediate T cell activation in a mouse T cell hybridoma line as well as
polyclonal activated mouse and human T cells. Such high-affinity scTv could potentially
improve TCR gene therapy formats, by avoiding the risk of TCR mispairing that is
associated with receptors containing human or mouse Cα and Cβ regions, or their mutated
variants. Furthermore, the higher affinity scTv would be capable of functioning independent
of CD8 to mediate the activity of CD4+ TH cells 74,75.
Another potential advantage of the scTv-fusion approach is that the endogenous TCR/CD3
complexes remain at the same level on the transduced T cell as on the parental cell. In a
study of T cells that expressed two transgenic TCRs, it was possible to overcome tolerance
mediated by one of the TCRs through signaling mediated by the other TCR 71. It has also
been shown that activation of T cells through the endogenous TCR can promote the
persistence of transduced T cells, thereby enhancing their effectiveness against the target
antigen of the transduced TCR 76,77. Thus, the ability of the scTv fusions to avoid
mispairing could preserve efficient signaling through the endogenous TCR and avoid the
formation of heterodimers of unknown specificity, yet allow the introduced scTv-fusion to
mediate re-directed activity against tumor or viral epitopes.
Materials and Methods
Peptides, antibodies, and cell lines
Peptides SIY (SIYRYYGL), OVA (SIINFEKL), SL9 (HIV-Gag, SLYNTVATL), Tax
(LLFGYPVYV) and WT-1 (RMFPNAPYL) peptides were synthesized by the
Macromolecular Core Facility at Penn State College of Medicine (Hershey, PA). Peptides
were purified by reverse-phase chromatography using a C18 column with mass confirmed
by MALDI.
The following antibodies were used: PE-conjugated anti-mouse CD3ε (BD Pharmingen,
Clone 145-2C11), anti-mouseVβ8.2 (Clone F23.2), 1B2 clonotypic antibody, anti-mouse
Vβ10 (Clone B21.5, eBiosciences), DimerX Db (BD Biosciences), PE-conjugated anti-
mouse CD8α (Clone 53–6.7, BD Pharmingen), goat anti-Mouse IgG AlexaFluor 647
(Molecular Probes) and anti-human Vβ5.2 (Clone 1C1, Pierce/Thermo Scientific). The 2C
clonotypic antibody 1B2 was purified from hybridoma supernatant by ammonium sulfate
precipitation followed by Protein G chromatography 78. Biotinylation of purified antibody
was performed using the EZ-Link Suflo-NHS-LC-Biotinylation Kit (Pierce).
The Plat-E (Clonetech) retroviral packaging cell line was maintained in DMEM with 10%
FCS, L-glutamine, penicillin and streptomycin. T2-Kb, a TAP-deficient cell line that can
present exogenous peptides, and 58−/− T cell hybridoma derived from an AKR thymoma
(H-2k) 41 were maintained in RPMI 1640 complete medium supplemented with 10% FCS,
L-glutamine, penicillin and streptomycin. The 58−/− T cell line was transduced with
retroviral supernatants of the full-length or scTv constructs as described 40.
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Three-domain and two-domain (scTv) constructs
Various TCR constructs (Figure 1) were cloned into a murine stem cell virus (MSCV)
retroviral vector 40. The two- and three-domain 2C and/or m33 single-chain TCR constructs
contained six stabilizing mutations identified by yeast display (Vβ: Glu17Val, His47Tyr,
Leu81Ser, Vα: Leu43Pro, Trp82Arg, Ile118Asn) 36,79. 2C TCR contains Vα3.1 (TRAV9-4)
and Vβ8.2 (TRBV13-2) gene segments. The three-domain TCR gene was codon optimized
(Genscript) in the Vα3-linker-Vβ8.2Cβ orientation with a nonnative cysteine at position 57
of the β chain constant region (Cβ: Ser57Cys), and introduced into the MSCV vector
through AgeI/MluI restriction sites. For generation of the m33 Vα-linker-VβCβ-
IRES-2CVαCα construct, the m33 three-domain construct was introduced into the 2C
MSCV vector in the AgeI and XhoI restriction sites, replacing the 2C VβCβ chain 40.
For generation of scTv chimeric antigen receptor constructs, the murine CD8α hinge, CD28,
CD3ζ, and LCK gene fusion was codon optimized (Genscript), based on sequences from the
NIH database (GenBank accession #AAS07035.1) 27. The CD8α hinge was derived from
scFv chimeric antigen receptor constructs previously described in murine systems 80, and
the m33 scTCR (Vα-linker-Vβ) amplified by PCR from the three domain construct with a
flanking 5’ AgeI restriction site. Subsequently, the scTv was fused to the CD8α hinge,
CD28, CD3ζ gene by overlap extension PCR with a primer that added a 3’ MluI restriction
site. The scTv gene fusion was introduced into the AgeI and MluI restriction sites of the
MSCV vector. A XhoI site exists at the 3’ end of the m33 scTCR, prior to the start of the
CD8α hinge region, allowing for introduction of other scTv genes with appropriate leader
sequences into the scTv CD28,CD3ζ,LCK fusion protein. The 2C scTv with wild type
CDR3α sequence (GFASA) was created by overlap extension PCR, and introduced into
AgeI and XhoI sites in the m33 scTv construct.
The human TCR 868 against the HIV Gag peptide called SL9 44 was synthesized as a
single-chain Tv 45. The 868 scTv gene was amplified by PCR from the pCT302 yeast
display vector, with a 5’ primer that contained the leader sequence of the 2C scTv and an
AgeI site, and a 3’ end primer which included a XhoI site. The 868 scTv was then
introduced into the m33 scTv vector containing CD8α hinge, CD28, CD3ζ, LCK fusion in
MSCV by the AgeI and XhoI sites, with the 868 scTCR replacing the m33 scTCR in the
fusion construct. The 868 scTv gene contained high-affinity CDR mutations derived from
phage-displayed, full-length TCR 44.
T cell hybridoma transductions
scTv and full-length TCR genes in MSCV were introduced into the Plat-E packaging line to
produce cell supernatant containing retrovirus for introduction into 58−/− T cells. The
retroviral packaging line was transfected with 40 µg of MSCV DNA with the lipofectamine
2000 reagent (Sigma) in Optimem serum-free media (Gibco). After four to six hours, cells
were washed with supplemented DMEM and placed in 6 mL supplemented RPMI. Forty-
eight hours later, supernatant was collected, filtered, and added to 58−/− T cell hybridoma
cells with lipofectamine at a final volume of 8 µl/mL. T cells were centrifuged in retroviral
supernatant at 1200 × g for 45 min at room temperature, cultured at 37°C for 3 days, and
stained for cell surface mouse Cβ, mouse Vβ8, or human Vβ5 (868 scTv) with antibodies
and analyzed on an Accuri C6 flow cytometer. To enrich for the transduced, positive
population, cells were sorted with either anti-mouse Vβ8 (F23.2) for 2C and m33 or anti-
human Vβ5.2 for 868, using a FACS Aria (BD Biosciences).
The 3D high-affinity TCR contained mouse Vα3 (TRAV9-1 subfamily, distinct from
TRAV9-4 of 2C TCR, also called Vα3.1), mouse Vβ10 (TRBV4), and CDR3 mutations that
conferred higher affinity for WT-1/Db (unpublished data), after isolation by T cell
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display 33. The 3D receptor contained unmodified TCR constant domains (Cα48:Thr,
Cβ57:Ser), and was introduced into the 58−/− line as described for scTv and three-domain
constructs. The 3D TCR+ population was sorted with anti-Cβ antibodies prior to
transduction of m33 scTv or m33 threedomain.
pepMHC multimer binding
Transduced cells were stained with SIY/Kb pepMHC tetramer on ice for 2 hours. SIY/Kb
tetramer was produced as has been described 40. After washing, cells were resuspended in
cold PBS/BSA and analyzed for bound fluorescent tetramers by flow cytometry. Non-
transduced T cell hybridoma 58−/− line was used as a control. Alternatively, WT-1/Db
pepMHC Ig-dimers (DimerX, BD Biosciences) were prepared by incubation overnight at
37°C with WT-1 peptide at 120-molar excess. Transduced cells were stained with WT-1/
DimerX for 2 hours on ice in the dark, washed twice with 10-fold excess volume PBS/BSA
(0.5%), and incubated on ice for 1 h in the dark with goat anti-mouse IgG APC Fab’ Alexa
Fluor 647 at 10 µg/mL (Molecular Probes).
T cell activation assays
T cells (7.5 × 104) were incubated with SIY or OVA peptide loaded T2-Kb cells (7.5 × 104),
plate bound antibodies (anti-CD3ε or anti-mouse Vβ8 (F23.2)), or plate bound pepMHC
tetramer (SIY/Kb or OVA/Kb) as described 40. For the 868 scTv cell line, cells were
incubated with plate-bound antigenic SL9 (HIV Gag)/HLA.A2 or null Tax/HLA.A2
streptavidin tetramers or SL9 or WT-1 peptide-loaded T2 cells (7.5 × 104). T cells were
incubated with the various stimuli for 24 h at 37°C in a final volume of 200 µL, and
supernatants were collected. For IL-2 detection, 96-well plates were coated with 2.5 µg/mL
anti-murine IL-2 (BD Pharmingen) in 0.1 M Na2HPO4 (pH=9.0), and IL-2 in supernatants
was detected with 6.7 µg/mL biotinylated anti-murine IL-2 (BD Pharmingen), followed by a
1/10,000 dilution of streptavidin-HRP (BD Pharmingen), and finally, TMB substrate
(Kirkegaard & Perry Laboratories). Absorbance at 450 nm was measured with an ELx800
universal plate reader (Bio-Tek Instruments).
Primary T cell transductions
Primary T cells were isolated from C57/BL6 splenocytes and treated with ACK lysis buffer
to remove RBCs. Subsequently, cells were separated into CD4 or CD8 T cell populations
using magnetic beads (MACS, Miltenyi Biotec). 1 × 106 purified cells were stimulated with
anti-CD3/anti-CD28 Dynabeads (Invitrogen) per manufacturer’s instructions and 30 U/mL
of IL-2 24 hours prior to transduction. Retroviral supernatant was prepared as described for
58−/− cells. Primary cells were centrifuged at 1200 xg, 30 °C for 1 hour (spinfection) with
full-length TCR, scTv fusion (CD28, 4-1BB, CD3ζ) or mock (no vector DNA) retroviral
supernatants, placed at 37 °C, 5% CO2 overnight followed by a second spinfection the next
morning.
For human T cell transductions, CD8+ T cells were purified from total donor PBMCs by
MACs purification using CD8 beads (Miltenyi Biotec). Purified CD8+ T cells were
stimulated by incubation at a 1:1 ratio with CD3/CD28 Dynabeads (Dynal Biotech) and then
transduced at 6 hours and 24 hours post-stimulation with lentiviral supernatants containing
virus encoding the TCR alpha and beta chains from the WT1-specific TCR, or supernatants
containing the retrovirus encoding the 868 scTv. Transductions were performed by
spinfection for 90 minutes at 2000 xg in a 32 °C centrifuge in the presence of 5µg/ml
Polybrene. Transduced T cells were cultured in 100 units of IL-2 for 7 days and then sorted
for human Vbeta5.2 and SL9 tetramer expression.
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For the m33 mouse T cell assays, transduced polyclonal CD4+ and CD8+ T cells were
cultured in the presence of IL-2 (20 U/mL, day 3 post-activation) and on day 6 cells were
incubated with 51Cr labeled T2-Kb cells pulsed with either 1 µM SIY or 1 µM OVA for four
hours at 37 °C at an effector to target ratio of 20:1. For human PBMCs, activated T cells
transduced with WT-1 specific αβTCR (mock) or 868 scTv were cultured with SL9 peptide
pulsed T2 cells. Supernatants were isolated and 51Cr was quantified for each sample using a
scintillation counter. Percent specific lysis was determined relative to spontaneous and
maximal 51Cr release.
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Full length, three-domain, and single-chain VαVβ (Tv) TCR constructs. TCRs derived from
the 2C or 3D TCR were introduced into the murine stem cell virus (MSCV) retroviral
vector. The m33 high affinity variant of the 2C TCR differs only in the CDR3α sequence:
2C CDR3α-GFASA, m33 CDR3α-LHRPA (designated by gray insert rectangle). The 3D
full-length receptor also contained CDR3α mutations that confer higher affinity to WT-1/Db.
The m33 three domain constructs contained a non-native cysteine mutation (Cβ: Cys57),
indicated by the black rectangle. IRES refers to internal ribosome entry site, CD28TM refers
to the CD28 transmembrane domain, and mVαL refers to the murine Vα leader sequence.
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Three-domain m33 TCR mispairs with endogenous TCR α chains. T cell hybridoma 58−/−
mock (no vector DNA) transduced cells (gray line) and transduced cells (black line) were
analyzed by flow cytometry for surface expression after transduction with (A) the m33
three-domain construct or (B) the m33 three-domain construct and the 2C full α chain
construct (2C VαCã̤ Transduced cells were examined with anti-Cβ antibody, SIY/Kb
Tetramer (100 nM) or 1B2 clonotypic antibody. The m33 three-domain cassettes in both
constructs contained a Cβ non-native cysteine while the 2C VαCα chain contained
unmodified constant domains. The schematic in (B) depicts the binding sites of SIY/Kb
tetramer and 1B2. A fraction of the receptors in (B) that mispair would bind to 1B2, and not
bind to SIY/Kb tetramer, while other properly associated three-domain receptors on the same
cell could bind to SIY/Kb tetramer.
Aggen et al. Page 17














Three-domain m33 TCR mispairs with endogenous TCR 3D. The WT-1 specific TCR 3D,
which contains unmodified murine constant domains, was used to mimic an endogenous
TCR (3D TCR: mVα3, mVβ10). 3D TCR-positive T cell hybridoma 58−/− were transduced
with the m33 three-domain TCR (Vβ8+) construct. Vβ8-sorted cells were analyzed with
anti-Vβ8 (A), anti-Vβ10 (B) or WT-1/Db DimerX at 125 nM (C). Transduced 3D cells that
co-express the m33 three-domain construct (gray line) were compared to cells that express
only the 3D full-length TCR (black line), or only the m33 three-domain construct (black
dashed line).
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A single-chain VαVβ TCR (scTv) construct avoids detectable mispairing with endogenous
TCR 3D. 3D expressing T cells were transduced as in Fig. 3, but in this instance with the
m33 scTv. Following sorting with anti-Vβ8 antibody, cells were analyzed with anti-Vβ8
(A), SIY/Kb tetramer at 100 nM (B) anti-Vβ10 (C), or WT-1/Db DimerX at 125 nM (D).
Transduced 3D cells that co-express the m33 scTv construct (gray line) were compared to
cells that express only the 3D full-length TCR (black line), or only the m33 scTv construct
(black dashed line).
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Surface levels and SIY/Kb binding by scTv and full-length TCRs. scTv and full-length 2C
(KD=30 µM for SIY/Kb) and m33 (KD=30 nM for SIY/Kb) constructs were introduced into
58−/− cells. Cell surface expression was monitored with anti-Vβ8 (A) or SIY/Kb SA:PE
labeled tetramer at 40 nM (B) by flow cytometry. SIY/Kb tetramer binding to scTv and full-
length constructs was examined at various concentrations of tetramer (C).
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Comparison of m33 (high affinity) and 2C (low affinity) full-length and scTv constructs for
antigen specific T cell activation. (A) CD3ε surface expression of the m33 scTv (gray line)
and full-length TCR (black line). (B) Activation of IL-2 release from m33 scTv and full-
length expressing cells with plate bound anti-Vβ8 or anti-CD3ε antibodies. (C) Antigen
specific activation of 2C and m33 scTv and full-length transduced cells using peptide-loaded
T2-Kb cell line at various concentrations of exogenous SIY peptide. (D) Antigen specific
activation of 2C and m33 scTv and full-length transduced cells using plate bound SIY/Kb
tetramer. (E) Cell surface levels of 2C scTv (as monitored with anti-Vβ8) and CD8α in 2C
scTv CD8αβ+ and CD8αβ- T cells. (F) Antigen specific activation of 2C scTv CD8− and
Aggen et al. Page 21













CD8+ transduced cells with peptide-loaded T2-Kb cell line at various concentrations of
exogenous SIY peptide. Data for B, C, and D, and F is representative of three independent
experiments for each panel. OVA peptide (10 µM) loaded T2-Kb cells and OVA/Kb plate-
bound pepMHC tetramer gave absorbance values from the IL-2 ELISA at background levels
(not shown).
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Comparison of m33 CD28, 4-1BB, CD3ζ scTv and m33 full-length TCR in T cell
cytotoxicity directed against SIY+ APCs. Full-length m33 αβ TCR or m33 CD28, 4-1BB,
CD3ζ scTv (m33 scTv) receptors were introduced into purified, activated CD8+ (A) or
CD4+ (B) primary C57Bl/6 T cells and T cell cytotoxicity was assessed in a 4-hour 51Cr
release assay with T2 target cells loaded with 1 µM exogenous SIY, OVA, or no peptide. T
cell effector to T2 target cell ratio was fixed at 20:1. Mock – splenocytes activated without
the addition of an endogenous receptor (untransduced).
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The human high-affinity HIV-specific 868 scTv mediates antigen-specific activity in 58−/−
T cells. (A) The leader from the 2C scTv was introduced upstream of the 868 scTv, and the
human TCR was expressed as a fusion to murine intracellular signaling subunits. (B)
Surface expression of 868 scTv in transduced cells was monitored by anti-human Vβ5.2.
(gray line - 58−/− cells, black line – 868 scTv). To assess antigen specific activation, 868
scTv expressing cells were stimulated with (C) SL9 or WT-1 (null) peptide loaded T2 cells
or (D) plate-bound SL9/A2 or Tax/A2 tetramers at various concentrations. Data in C and D
are representative of two independent experiments for each panel. (E) T cell cytotoxicity
with human PBMCs transduced with a WT-1 specific TCR (mock) or 868 scTv with T2
target cells pulsed with exogenous SL9 (10 µM) peptide. Data in E is representative of two
experiments.
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